Loading
A phase 1/2 trial of TUB-030 in small-cell lung cancer, non-small-cell lung cancer and triple-negative breast cancer, run by Tubulis GmbH, now recruiting.
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06657222 by Tubulis GmbH, with 250 participants planned, started 2024-12-13 and due to reach its primary completion in 2028-12. Interventions recorded: TUB-030.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tubulis (Gilead), Non-small-cell lung cancer and the tag pipeline.
Shares Tubulis (Gilead) and the tag pipeline.
Shares Small-cell lung cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/